AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Study of novel anticancer agent gets boost from $3M grant.
2003 NOV 6 - (NewsRx.com & NewsRx.net) -- Roswell Park Cancer Institute (RPCI) has been awarded a Clinical Translational Research Grant of $3,089,794 by the Breast Cancer Research Program of the U.S. Department of Defense for the study of a vascular-targeting anti-angiogenic therapy of human breast cancer.
Ben K. Seon, PhD, Department of Immunology, RPCI, is the principal investigator.
Seon and his colleagues will test the safety and antitumor effect of a novel cancer agent in Phase I and II clinical trials in breast cancer patients. The agent, a monoclonal antibody (mAb) developed in Seon's laboratory, ...
- Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st...
- Press release article from: PR Newswire December 12, 2008 700+ words
...BN107 at the 31st Annual San Antonio Breast Cancer Symposium being held at the Henry B...only in estrogen receptor negative breast cancer cells. Our studies show that cholesterol...constituting 40% of women diagnosed with breast cancer, is chemotherapy. BN107, an oral...
- Bionovo to Present Recent Findings of BN108, its Anticancer Agent, at the 31st...
- Press release article from: PR Newswire December 12, 2008 700+ words
...Inc. will present findings on the mechanism of action of its anti-cancer agent BN108 at the 31st Annual San Antonio Breast Cancer Symposium being held at the Henry B. Gonzalez Convention Center, San Antonio TX, December 10-14, 2008. Bionovo's...
- NEW ANTICANCER AGENT, TAXOTERE(R) (docetaxel), NOW AVAILABLE TO TREAT ADVANCED...
- Press release article from: PR Newswire January 19, 1996 700+ words
...agent for the treatment of advanced breast cancer, is now available in Ireland, where...500 women diagnosed each year with breast cancer. Ireland is one of the first countries...agent in the treatment of advanced breast cancer resistant to the most common available...
- TAXOTERE(R) (DOCETAXEL) RECEIVES APPROVAL FOR BREAST AND NON-SMALL CELL LUNG...
- Press release article from: PR Newswire February 2, 1995 700+ words
...docetaxel), a new anticancer agent, was approved for...patients with advanced breast cancer who have not received...chemotherapy; advanced breast cancer patients who have...a commonly used anticancer agent; advanced NSCLC...
- FMdC Clinical Results Reported at ASCO Meeting; Novel Anticancer Agent Well...
- Press release article from: Business Wire May 17, 1999 700+ words
...cancer. IntraDose is a collagen-con locally injected gel containing the anticancer agent fluorouracil, is in a Phase I/II trial in recurrent and metastatic breast cancer. This press release contains certain statements of a forward-looking...
- Taxotere(R), New Anticancer Agent, First Taxoid to be Launched in Japan; Japan...
- Press release article from: PR Newswire June 20, 1997 700+ words
...docetaxel), its new anticancer agent, is now commercially...small-cell lung and breast cancer. Taxotere is the...and patients a new anticancer agent that helps combat...000 new cases of breast cancer and 58,000 of non...
- RHONE-POULENC RORER: STUDY INDICATES THAT NEW ANTICANCER AGENT IS HIGHLY...
- Press release article from: PR Newswire October 31, 1995 700+ words
...PRNewswire/ -- A new anticancer agent, Taxotere(R...Taxotere is a new anticancer agent that inhibits cancer...patients with advanced breast cancer and non-small cell...treatment of advanced breast cancer when previous anthracycline...
- New Anticancer Agent Taxotere(R) Cleared for Use in Japan; First Taxoid to be...
- Press release article from: PR Newswire October 28, 1996 700+ words
...announced today that its new anticancer agent Taxotere(R) (docetaxel...small cell lung cancer and breast cancer. Taxotere is now approved for...Now physicians will have a new anticancer agent to treat two of the five most...
Source: HighBeam Research, Study of novel anticancer agent gets boost from $3M grant.